Stay updated with breaking news from Orca Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Encouraging data with RFS, OS, and NRM for Orca-T was also matched in a population of patients with hematologic cancers aged 55 years and older.
The high-precision cellular product Orca-Q demonstrated early signals of clinical activity as well as an acceptable safety profile for patients undergoing haploidentical stem cell transplantation without posttransplant cyclophosphamide.
– Orca-T, Orca Bio’s lead investigational high-precision cell therapy, showed similar results in older patients undergoing myeloablative conditioning as seen in younger patients across disease control, non-relapse mortality and overall survival –– Orca-T in older patients given a reduced intensity conditioning regim...
Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.
Jonathan MacQuitty talks about cell and gene therapy shortcomings and the challenges for private companies at different funding stages in 2023.